Consequences of dysregulated complement regulators on red blood cells.

The complement system represents the first line of defense that is involved in the clearance of pathogens, dying cells and immune complexes via opsonization, induction of an inflammatory response and the formation of a lytic pore. Red blood cells (RBCs) are very important for the delivery of oxygen to tissues and are continuously in contact with complement proteins in the blood plasma. To prevent complement activation on RBCs, various complement regulatory proteins can be found in plasma and on the cell membrane. RBCs are special cells without a nucleus and having a slightly different make-up of complement regulators than nucleated cells, as membrane cofactor protein (MCP) is not expressed and complement receptor 1 (CR1) is highly expressed. Decreased expression and/or function of complement regulatory proteins may result in unwanted complement activation and accelerated removal of RBCs. This review describes complement regulation on RBCs and the consequences when this regulation is out of balance.

• Publication year

  2018

• Venue

  Blood reviews

• Publication date

  2018-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.blre.2018.01.003PMID 29397262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Complement Dysregulation and Disease: Insights from Contemporary Genetics.

  2017cited by this paper
• Autoimmune Hemolytic Anemia.

  2017cited by this paper
• Expression pattern of CD55 and CD59 on red blood cells in sickle cell disease

  2017cited by this paper
• How I treat autoimmune hemolytic anemia.

  2017cited by this paper
• Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes

  2017cited by this paper
• Complement in clinical medicine: Clinical trials, case reports and therapy monitoring

  2017cited by this paper
• Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway

  2016cited by this paper
• Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

  2016cited by this paper
• The membrane attack complex as an inflammatory trigger.

  2016cited by this paper
• Protection of host cells by complement regulators

  2016cited by this paper
• C4b-binding protein: The good, the bad and the deadly. Novel functions of an old friend.

  2016cited by this paper
• Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

  2016cited by this paper
• Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.

  2016cited by this paper
• Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome.

  2016cited by this paper
• Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

  2016cited by this paper
• Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study

  2016cited by this paper
• Complement inhibitors to treat IgM-mediated autoimmune hemolysis

  2015cited by this paper
• Shiga Toxin–Induced Complement-Mediated Hemolysis and Release of Complement-Coated Red Blood Cell–Derived Microvesicles in Hemolytic Uremic Syndrome

  2015cited by this paper
• Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review

  2015cited by this paper
• Compensation of CD55 Underexpression on Red Blood Cells of β-Thalassemia Major Patients

  2015cited by this paper
• Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.

  2015cited by this paper
• A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion

  2015cited by this paper
• Targeted therapy with eculizumab for inherited CD59 deficiency.

  2014cited by this paper
• The involvement of cation leaks in the storage lesion of red blood cells

  2014cited by this paper
• Storage of RBCs results in an increased susceptibility for complement‐mediated degradation

  2014cited by this paper
• TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.

  2014cited by this paper
• Expression of CD55 on Red Blood Cells of β-Thalassemia Patients

  2014cited by this paper
• Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

  2014cited by this paper
• Membrane attack complex generation increases as a function of time in stored blood

  2014cited by this paper
• Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape

  2014cited by this paper
• Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

  2013cited by this paper
• Hematological Disorders in Patients with Systemic Lupus Erythematosus

  2013cited by this paper
• Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.

  2013cited by this paper
• C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia.

  2013cited by this paper
• Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies.

  2013cited by this paper
• Functional anatomy of complement factor H.

  2013cited by this paper
• CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy.

  2013cited by this paper
• Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties

  2013cited by this paper
• Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria.

  2013cited by this paper
• The tick-over theory revisited: is C3 a contact-activated protein?

  2012cited by this paper
• The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.

  2012cited by this paper
• Time-course investigation of SAGM-stored leukocyte-filtered red bood cell concentrates: from metabolism to proteomics

  2012cited by this paper
• Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*

  2012cited by this paper
• Diminished Expression of Complement Regulatory Proteins on Peripheral Blood Cells from Systemic Lupus Erythematosus Patients

  2012cited by this paper
• How I treat thalassemia.

  2011cited by this paper
• Red cell storage and prognosis

  2011cited by this paper
• Systemic lupus erythematosus serum deposits C4d on red blood cells, decreases red blood cell membrane deformability, and promotes nitric oxide production.

  2011cited by this paper
• Early and extensive CD55 loss from red blood cells supports a causal role in malarial anaemia

  2011cited by this paper
• Complement Receptor 1 Is a Sialic Acid-Independent Erythrocyte Receptor of Plasmodium falciparum

  2010cited by this paper
• Heme Degradation and Vascular Injury

  2010cited by this paper
• Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.

  2010cited by this paper
• Paths reunited: Initiation of the classical and lectin pathways of complement activation.

  2010cited by this paper
• Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

  2010cited by this paper
• Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients.

  2010cited by this paper
• Complement: a key system for immune surveillance and homeostasis

  2010cited by this paper
• Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand

  2010cited by this paper
• The Binding of Factor H to a Complex of Physiological Polyanions and C3b on Cells Is Impaired in Atypical Hemolytic Uremic Syndrome1

  2009cited by this paper
• Mutations of Factor H Impair Regulation of Surface-bound C3b by Three Mechanisms in Atypical Hemolytic Uremic Syndrome*

  2009cited by this paper
• Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal‐regulatory protein‐α,β on monocytes from patients with warm autoimmune hemolytic anemia

  2009cited by this paper
• Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus.

  2009cited by this paper
• Complement regulators and inhibitory proteins

  2009cited by this paper
• Malaria, erythrocytic infection, and anemia.

  2009cited by this paper
• Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.

  2008cited by this paper
• Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection.

  2008cited by this paper
• Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: Implications for the development of severe anemia

  2008cited by this paper
• Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.

  2008cited by this paper
• Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods

  2008cited by this paper
• Biological activities of C1 inhibitor.

  2008cited by this paper
• Reduced Immune Complex Binding Capacity and Increased Complement Susceptibility of Red Cells from Children with Severe Malaria-Associated Anemia

  2008cited by this paper
• Coagulation in the pathophysiology of hemolytic anemias.

  2007cited by this paper
• Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

  2007cited by this paper
• Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

  2007cited by this paper
• Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes.

  2007cited by this paper
• Hematin Promotes Complement Alternative Pathway-Mediated Deposition of C3 Activation Fragments on Human Erythrocytes: Potential Implications for the Pathogenesis of Anemia in Malaria1

  2007cited by this paper
• Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.

  2007cited by this paper
• Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins.

  2007cited by this paper
• Macrophage complement receptors and pathogen clearance

  2007cited by this paper
• Gene for human CD59 (likely Ly-6 homologue) is located on the short arm of chromosome 11

  2006cited by this paper
• Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

  2006cited by this paper
• Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome

  2006cited by this paper
• Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

  2005cited by this paper
• Destabilisation and subsequent lysis of human erythrocytes induced by Plasmodium falciparum haem products

  2005cited by this paper
• Low Erythrocyte Complement Receptor Type 1 (CR1, CD35) Expression in Preeclamptic Gestations

  2005cited by this paper
• Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions.

  2005cited by this paper
• Anemia in Systemic lupus erythematosus: from pathophysiology to clinical assessment

  2005cited by this paper
• Free heme toxicity and its detoxification systems in human.

  2005cited by this paper
• Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32.

  2005cited by this paper
• Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.

  2004cited by this paper
• The role of complement in the development of systemic lupus erythematosus.

  2004cited by this paper
• Four Viruses, Two Bacteria, and One Receptor: Membrane Cofactor Protein (CD46) as Pathogens' Magnet

  2004cited by this paper
• A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria

  2003cited by this paper
• Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus.

  2003cited by this paper
• Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia.

  2003cited by this paper
• CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b‐8 as well as C5b‐9

  2002cited by this paper
• Storage of red blood cells: new approaches.

  2002cited by this paper
• Visualization of the transfer reaction: tracking immune complexes from erythrocyte complement receptor 1 to macrophages.

  2002cited by this paper
• Defective Regulation of Complement by the Sickle Erythrocyte: Evidence for a Defect in Control of Membrane Attack Complex Formation

  2002cited by this paper
• Complement. First of two parts.

  2001cited by this paper
• Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.

  2001cited by this paper
• The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.

  2001cited by this paper

• A Review of the Knops Blood Group System

  2024cites this paper
• Immunological Changes and Complement Proteins in Major Thalassemia Patients Proteins Post-Splenectomy

  2024cites this paper
• ABO Blood Groups, Rhesus Factor, and Rheumatoid Arthritis

  2024cites this paper
• Red blood cell-derived materials for cancer therapy: Construction, distribution, and applications

  2023cites this paper
• C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia

  2023cites this paper
• Biomimetic nanoparticles targeting atherosclerosis for diagnosis and therapy

  2023cites this paper
• A guide to complement biology, pathology and therapeutic opportunity

  2023cites this paper
• Complement C3b contributes to Escherichia coli-induced platelet aggregation in human whole blood

  2022influential citation
• Evolution of red blood cell membrane complement regulatory proteins and rheology in septic patients: An exploratory study

  2022cites this paper
• Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)

  2022cites this paper
• Low‐molecular weight inhibitors of the alternative complement pathway

  2022cites this paper
• Promote Intratumoral Drug Release and Penetration to Counteract Docetaxel‐Induced Metastasis by Photosensitizer‐Modified Red Blood Cell Membrane‐Coated Nanoparticle

  2022cites this paper
• Purification of novel polypeptides from bee pupae and their immunomodulatory activity in vivo and in vitro

  2022cites this paper
• Erythrocyte Auto-Antibodies against Complement Regulatory Proteins of the Erythrocyte Membrane

  2021cites this paper
• Halting targeted and collateral damage to red blood cells by the complement system

  2021cites this paper
• Human erythrocytes, nuclear factor kappaB (NFκB) and hydrogen sulfide (H2S) – from non-genomic to genomic research

  2021cites this paper
• Clinical Impact of the ABO Blood Type in Patients with Rheumatic Diseases: Is there a Link to the ABO and Rhesus?

  2021cites this paper
• Specificities and isotypes of erythrocytes autoantibodies in patients with warm autoimmune hemolytic anemia

  2021cites this paper
• Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy

  2021cites this paper
• Coronavirus disease 2019 (COVID-19), human erythrocytes and the PKC-alpha/-beta inhibitor chelerythrine –possible therapeutic implication

  2020cites this paper
• The role of complement in antibody-dependent acquired immunity to Plasmodium falciparum malaria

  2020cites this paper
• Novel molecular plasma signatures on cardiovascular disease can stratify patients throughout life.

  2020cites this paper
• Edinburgh Research Explorer Rosetting revisited

  2019cites this paper
• The Many Faces of Thrombotic Microangiopathies

  2019influential citation
• Rosetting revisited: a critical look at the evidence for host erythrocyte receptors in Plasmodium falciparum rosetting

  2019cites this paper
• Nucleated Red Blood Cells Contribute to the Host Immune Response Against Pathogens

  2018cites this paper